|
Murcia L, Carrilero B, Saura D, Iborra MA, Segovia M. [Diagnosis and treatment of Chagas disease]. Enferm Infecc Microbiol Clin. 2013 Feb;31 Suppl 1:26-34. doi: 10.1016/S0213-005X(13)70111-3. Spanish. PubMed PMID: 23453228.
AÑO: 2013; IF: 1.881
|
23453228
|
Murcia L, Carrilero B, Segovia M. Limitations of currently available Chagas disease chemotherapy. Rev Esp Quimioter. 2012 Mar;25(1):1-3. PubMed PMID: 22488534.
AÑO: 2012; IF: 0.836
|
|
Iborra-Bendicho MA, Albert-Hernández M, Márquez-Contreras C, Segovia-Hernández M. [ARCHITECT Chagas(®): a new diagnostic tool in Chagas disease]. Enferm Infecc Microbiol Clin. 2012 Oct;30(8):463-5. doi: 10.1016/j.eimc.2012.02.002. Epub 2012 Mar 23. Spanish. PubMed PMID: 22446008.
AÑO: 2012; IF: 1.478
|
|
Thomas MC, Fernández-Villegas A, Carrilero B, Marañón C, Saura D, Noya O, Segovia M, Alarcón de Noya B, Alonso C, López MC. Characterization of an immunodominant antigenic epitope from Trypanosoma cruzi as a biomarker of chronic Chagas' disease pathology. Clin Vaccine Immunol. 2012 Feb;19(2):167-73. doi: 10.1128/CVI.05566-11. Epub 2011 Dec 7. PubMed PMID: 22155766; PubMed Central PMCID: PMC3272920.
AÑO: 2012; IF: 2.598
|
|
Egui A, Thomas MC, Morell M, Marañón C, Carrilero B, Segovia M, Puerta CJ, Pinazo MJ, Rosas F, Gascón J, López MC. Trypanosoma cruzi paraflagellar rod proteins 2 and 3 contain immunodominant CD8(+) T-cell epitopes that are recognized by cytotoxic T cells from Chagas disease patients. Mol Immunol. 2012 Oct;52(3-4):289-98. doi: 10.1016/j.molimm.2012.05.021. Epub 2012 Jun 29. PubMed PMID: 22750229.
AÑO: 2012; IF: 2.645
|